JNJ Johnson & Johnson
NYSE · SEC CIK 200406 · EDGAR
- Bought, last 12 months
- $257.7K 1 purchases by 1 insiders
- Sold, last 12 months
- $154.85M 16 sales by 10 insiders
- Filings on record
- 335 since 2021-09-09, latest 2026-09-10 20:51
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Duato Joaquin | CEO, COB, Dir | — | $66.84M |
| Wolk Joseph J | EVP, CFO | — | $21.77M |
| REED JOHN C | EVP, Innovative Medicine, R, D | — | $17.29M |
| Swanson James D. | EVP, CIO | — | $15.11M |
| Schmid Timothy | EVP, WW COB, MedTech | — | $15.08M |
| Broadhurst Vanessa | EVP, Gbl Corp Affairs | — | $7.30M |
| Forminard Elizabeth | EVP, CLO | — | $4.09M |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | — | $3.95M |
| Wengel Kathryn E | EVP, Chief TO, Risk Off | — | $2.41M |
| Decker Robert J | VP Corp. Ctrl | — | $1.01M |
Transactions 353
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-09-04 09:08 | 2026-09-02 | JNJ | Schmid Timothy | EVP, WW COB, MedTech | M - OptEx | $144.99 | +33.6K | 48.0K | +234% | +$4.87M |
| DM | 2026-09-04 09:08 | 2026-09-02 | JNJ | Schmid Timothy | EVP, WW COB, MedTech | S - Sale+OE | $274.74 | -33.6K | 25.4K | -57% | -$9.23M |
| D | 2026-08-18 18:31 | 2026-08-17 | JNJ | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M - OptEx | $115.67 | +15.0K | 209.5K | +8% | +$1.74M |
| D | 2026-08-18 18:31 | 2026-08-17 | JNJ | Taubert Jennifer L | EVP, WWC. Innovative Medicine | S - Sale+OE | $263.36 | -15.0K | 194.5K | -7% | -$3.95M |
| D | 2026-08-14 16:35 | 2026-08-13 | JNJ | Duato Joaquin | CEO, COB, Dir | M - OptEx | $115.67 | +123.3K | 399.3K | +45% | +$14.26M |
| DM | 2026-08-14 16:35 | 2026-08-13 | JNJ | Duato Joaquin | CEO, COB, Dir | S - Sale+OE | $261.17 | -123.3K | 276.0K | -31% | -$32.20M |
| M | 2026-08-07 17:50 | 2026-08-05 | JNJ | Duato Joaquin | CEO, COB, Dir | S - Sale | $258.15 | -48.5K | 276.0K | -15% | -$12.52M |
| D | 2026-08-07 17:44 | 2026-08-06 | JNJ | Forminard Elizabeth | EVP, CLO | M - OptEx | $131.94 | +9,344 | 32.9K | +40% | +$1.23M |
| DM | 2026-08-07 17:44 | 2026-08-06 | JNJ | Forminard Elizabeth | EVP, CLO | S - Sale+OE | $257.00 | -15.9K | 17.0K | -48% | -$4.09M |
| DM | 2026-07-21 17:27 | 2026-07-20 | JNJ | Broadhurst Vanessa | EVP, Gbl Corp Affairs | M - OptEx | $130.77 | +23.1K | 46.1K | +100% | +$3.01M |
| D | 2026-07-21 17:27 | 2026-07-20 | JNJ | Broadhurst Vanessa | EVP, Gbl Corp Affairs | S - Sale+OE | $251.27 | -23.1K | 23.0K | -50% | -$5.79M |
| D | 2026-06-12 17:23 | 2026-06-11 | JNJ | Wengel Kathryn E | EVP, Chief TO, Risk Off | M - OptEx | $115.67 | +10.0K | 124.3K | +9% | +$1.16M |
| D | 2026-06-12 17:23 | 2026-06-11 | JNJ | Wengel Kathryn E | EVP, Chief TO, Risk Off | S - Sale+OE | $241.15 | -10.0K | 114.3K | -8% | -$2.41M |
| D | 2026-05-04 16:58 | 2026-05-01 | JNJ | REED JOHN C | EVP, Innovative Medicine, R, D | M - OptEx | $0.00 | +25.3K | 35.9K | +237% | $0 |
| D | 2026-05-04 16:58 | 2026-05-01 | JNJ | REED JOHN C | EVP, Innovative Medicine, R, D | F - Tax | $229.85 | -11.0K | 24.9K | -31% | -$2.53M |
| D | 2026-03-03 16:21 | 2026-02-27 | JNJ | Decker Robert J | VP Corp. Ctrl | M - OptEx | $115.67 | +4,075 | 27.8K | +17% | +$471.4K |
| D | 2026-03-03 16:21 | 2026-02-27 | JNJ | Decker Robert J | VP Corp. Ctrl | S - Sale+OE | $247.87 | -4,075 | 23.7K | -15% | -$1.01M |
| 2026-02-23 17:20 | 2026-02-20 | JNJ | Schmid Timothy | EVP, WW COB, MedTech | S - Sale | $245.66 | -1,322 | 25.4K | -5% | -$324.8K | |
| DM | 2026-02-18 21:12 | 2026-02-13+ | JNJ | Swanson James D. | EVP, CIO | M - OptEx | $139.50 | +73.1K | 46.2K | New | +$10.20M |
| DM | 2026-02-18 21:12 | 2026-02-13+ | JNJ | Swanson James D. | EVP, CIO | F - Tax | $244.41 | -4,213 | 25.7K | -14% | -$1.03M |
| DM | 2026-02-18 21:12 | 2026-02-13+ | JNJ | Swanson James D. | EVP, CIO | S - Sale+OE | $243.39 | -62.1K | 25.7K | -71% | -$15.11M |
| DM | 2026-02-18 21:12 | 2026-02-13+ | JNJ | Wengel Kathryn E | EVP, Chief TO, Risk Off | M - OptEx | $0.00 | +15.6K | 114.6K | +16% | $0 |
| DM | 2026-02-18 21:12 | 2026-02-13+ | JNJ | Wengel Kathryn E | EVP, Chief TO, Risk Off | F - Tax | $244.45 | -7,266 | 114.3K | -6% | -$1.78M |
| DM | 2026-02-18 21:12 | 2026-02-13+ | JNJ | Mulholland Kristen | EVP, Chief HR Off | M - OptEx | $0.00 | +5,006 | 20.1K | +33% | $0 |
| DM | 2026-02-18 21:12 | 2026-02-13+ | JNJ | Mulholland Kristen | EVP, Chief HR Off | F - Tax | $244.26 | -1,585 | 19.8K | -7% | -$387.1K |
| DM | 2026-02-18 21:12 | 2026-02-13+ | JNJ | Wolk Joseph J | EVP, CFO | M - OptEx | $76.02 | +107.8K | 72.3K | New | +$8.19M |
| DM | 2026-02-18 21:12 | 2026-02-13+ | JNJ | Wolk Joseph J | EVP, CFO | F - Tax | $244.45 | -18.1K | 39.0K | -32% | -$4.43M |
| DM | 2026-02-18 21:12 | 2026-02-17 | JNJ | Wolk Joseph J | EVP, CFO | S - Sale+OE | $242.80 | -89.7K | 14.0K | -86% | -$21.77M |
| DM | 2026-02-18 21:12 | 2026-02-13+ | JNJ | Decker Robert J | VP Corp. Ctrl | M - OptEx | $0.00 | +3,736 | 23.8K | +19% | $0 |
| DM | 2026-02-18 21:12 | 2026-02-13+ | JNJ | Decker Robert J | VP Corp. Ctrl | F - Tax | $244.35 | -1,055 | 23.7K | -4% | -$257.8K |
| DM | 2026-02-18 21:12 | 2026-02-15+ | JNJ | REED JOHN C | EVP, Innovative Medicine, R, D | M - OptEx | $147.75 | +54.8K | 42.9K | New | +$8.10M |
| DM | 2026-02-18 21:12 | 2026-02-15 | JNJ | REED JOHN C | EVP, Innovative Medicine, R, D | F - Tax | $243.45 | -913 | 12.9K | -7% | -$222.3K |
| DM | 2026-02-18 21:12 | 2026-02-17 | JNJ | REED JOHN C | EVP, Innovative Medicine, R, D | S - Sale+OE | $243.00 | -53.9K | 10.7K | -83% | -$13.11M |
| DM | 2026-02-18 21:11 | 2026-02-13+ | JNJ | Forminard Elizabeth | EVP, CLO | M - OptEx | $0.00 | +16.4K | 24.1K | +212% | $0 |
| DM | 2026-02-18 21:11 | 2026-02-13+ | JNJ | Forminard Elizabeth | EVP, CLO | F - Tax | $244.41 | -8,361 | 23.6K | -26% | -$2.04M |
| DM | 2026-02-18 21:11 | 2026-02-13+ | JNJ | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M - OptEx | $0.00 | +32.2K | 195.4K | +20% | $0 |
| DM | 2026-02-18 21:11 | 2026-02-13+ | JNJ | Taubert Jennifer L | EVP, WWC. Innovative Medicine | F - Tax | $244.43 | -15.7K | 194.5K | -7% | -$3.84M |
| DM | 2026-02-18 21:11 | 2026-02-13+ | JNJ | Schmid Timothy | EVP, WW COB, MedTech | M - OptEx | $92.76 | +29.6K | 35.8K | +476% | +$2.74M |
| DM | 2026-02-18 21:11 | 2026-02-13+ | JNJ | Schmid Timothy | EVP, WW COB, MedTech | F - Tax | $244.33 | -2,287 | 26.8K | -8% | -$558.8K |
| DM | 2026-02-18 21:11 | 2026-02-18 | JNJ | Schmid Timothy | EVP, WW COB, MedTech | S - Sale+OE | $244.33 | -22.6K | 26.8K | -46% | -$5.53M |
| DM | 2026-02-18 21:11 | 2026-02-13+ | JNJ | Duato Joaquin | CEO, COB, Dir | M - OptEx | $0.00 | +84.7K | 326.4K | +35% | $0 |
| DM | 2026-02-18 21:11 | 2026-02-13+ | JNJ | Duato Joaquin | CEO, COB, Dir | F - Tax | $244.44 | -36.2K | 324.4K | -10% | -$8.86M |
| DM | 2026-02-18 21:11 | 2026-02-13+ | JNJ | Broadhurst Vanessa | EVP, Gbl Corp Affairs | M - OptEx | $0.00 | +10.0K | 29.5K | +52% | $0 |
| DM | 2026-02-18 21:11 | 2026-02-13+ | JNJ | Broadhurst Vanessa | EVP, Gbl Corp Affairs | F - Tax | $244.42 | -4,414 | 29.2K | -13% | -$1.08M |
| D | 2026-02-18 21:11 | 2026-02-17 | JNJ | Broadhurst Vanessa | EVP, Gbl Corp Affairs | S - Sale+OE | $243.39 | -6,197 | 23.0K | -21% | -$1.51M |
| D | 2026-02-10 21:46 | 2026-02-06 | JNJ | Schmid Timothy | EVP, WW COB, MedTech | M - OptEx | $101.87 | +15.6K | 32.5K | +92% | +$1.59M |
| D | 2026-02-10 21:46 | 2026-02-06 | JNJ | Schmid Timothy | EVP, WW COB, MedTech | F - Tax | $239.99 | -10.3K | 22.1K | -32% | -$2.48M |
| D | 2026-02-09 19:42 | 2026-02-06 | JNJ | Mulholland Kristen | EVP, Chief HR Off | M - OptEx | $101.87 | +5,625 | 19.7K | +40% | +$573.0K |
| D | 2026-02-09 19:42 | 2026-02-06 | JNJ | Mulholland Kristen | EVP, Chief HR Off | F - Tax | $239.99 | -3,335 | 16.4K | -17% | -$800.4K |
| D | 2026-02-09 19:40 | 2026-02-06 | JNJ | Wengel Kathryn E | EVP, Chief TO, Risk Off | M - OptEx | $101.87 | +38.9K | 133.2K | +41% | +$3.97M |
| D | 2026-02-09 19:40 | 2026-02-06 | JNJ | Wengel Kathryn E | EVP, Chief TO, Risk Off | F - Tax | $239.99 | -27.3K | 106.0K | -20% | -$6.54M |
| D | 2026-02-06 17:46 | 2026-02-05 | JNJ | Forminard Elizabeth | EVP, CLO | M - OptEx | $129.51 | +8,921 | 21.8K | +69% | +$1.16M |
| D | 2026-02-06 17:46 | 2026-02-05 | JNJ | Forminard Elizabeth | EVP, CLO | F - Tax | $237.90 | -6,226 | 15.5K | -29% | -$1.48M |
| MI | 2026-01-28 18:07 | 2026-01-26 | JNJ | Duato Joaquin | CEO, COB, Dir | S - Sale | $221.23 | -100.0K | 30.9K | -76% | -$22.12M |
| 2025-12-01 16:15 | 2025-11-26 | JNJ | MORIKIS JOHN G | Dir | P - Purchase | $206.15 | +1,250 | 1,849 | +209% | +$257.7K | |
| D | 2025-10-20 19:13 | 2025-10-17 | JNJ | REED JOHN C | EVP, Innovative Medicine, R, D | M - OptEx | $157.92 | +21.7K | 32.4K | +204% | +$3.43M |
| D | 2025-10-20 19:13 | 2025-10-17 | JNJ | REED JOHN C | EVP, Innovative Medicine, R, D | S - Sale+OE | $192.71 | -21.7K | 10.7K | -67% | -$4.19M |
| D | 2025-09-05 18:00 | 2025-09-04 | JNJ | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M - OptEx | $101.87 | +56.5K | 234.5K | +32% | +$5.75M |
| D | 2025-09-05 18:00 | 2025-09-04 | JNJ | Taubert Jennifer L | EVP, WWC. Innovative Medicine | S - Sale+OE | $177.81 | -56.5K | 178.0K | -24% | -$10.04M |
| D | 2025-09-03 17:13 | 2025-08-29 | JNJ | Forminard Elizabeth | GC, Executive VP | M - OptEx | $115.67 | +11.5K | 22.4K | +106% | +$1.33M |
| D | 2025-09-03 17:13 | 2025-08-29 | JNJ | Forminard Elizabeth | GC, Executive VP | F - Tax | $177.20 | -9,570 | 12.9K | -43% | -$1.70M |
| D | 2025-08-25 19:12 | 2025-08-22 | JNJ | Duato Joaquin | CEO, COB, Dir | M - OptEx | $101.87 | +125.8K | 401.8K | +46% | +$12.82M |
| D | 2025-08-25 19:12 | 2025-08-22 | JNJ | Duato Joaquin | CEO, COB, Dir | S - Sale+OE | $179.21 | -125.8K | 276.0K | -31% | -$22.55M |
| D | 2025-08-18 18:19 | 2025-08-15 | JNJ | Wolk Joseph J | EVP, CFO | M - OptEx | $101.87 | +16.8K | 30.8K | +120% | +$1.71M |
| D | 2025-08-18 18:19 | 2025-08-15 | JNJ | Wolk Joseph J | EVP, CFO | S - Sale+OE | $176.91 | -16.8K | 14.0K | -55% | -$2.98M |
| 2025-07-18 16:12 | 2025-07-17 | JNJ | REED JOHN C | EVP, Innovative Medicine, R, D | S - Sale | $163.55 | -19.1K | 10.7K | -64% | -$3.13M | |
| D | 2025-05-05 17:10 | 2025-05-01 | JNJ | REED JOHN C | EVP, Innovative Medicine, R, D | M - OptEx | $0.00 | +25.3K | 40.8K | +162% | $0 |
| D | 2025-05-05 17:10 | 2025-05-01 | JNJ | REED JOHN C | EVP, Innovative Medicine, R, D | F - Tax | $156.31 | -11.0K | 29.8K | -27% | -$1.72M |
| 2025-03-19 20:07 | 2025-03-18 | JNJ | Duato Joaquin | CEO, COB, Dir | G - Gift | $0.00 | -130.9K | 276.0K | -32% | $0 | |
| I | 2025-03-19 20:07 | 2025-03-18 | JNJ | Duato Joaquin | CEO, COB, Dir | G - Gift | $0.00 | +130.9K | 130.9K | New | $0 |
| D | 2025-02-26 18:42 | 2025-02-25 | JNJ | Decker Robert J | VP Corp. Ctrl | M - OptEx | $101.87 | +6,999 | 28.0K | +33% | +$713.0K |
| D | 2025-02-26 18:42 | 2025-02-25 | JNJ | Decker Robert J | VP Corp. Ctrl | S - Sale+OE | $165.88 | -6,999 | 21.0K | -25% | -$1.16M |
| D | 2025-02-18 21:46 | 2025-02-14 | JNJ | Schmid Timothy | EVP, WW COB, MedTech | M - OptEx | $0.00 | +2,806 | 17.9K | +19% | $0 |
| D | 2025-02-18 21:46 | 2025-02-14 | JNJ | Schmid Timothy | EVP, WW COB, MedTech | F - Tax | $156.71 | -1,015 | 16.9K | -6% | -$159.1K |
| DM | 2025-02-18 21:33 | 2025-02-13+ | JNJ | Schmid Timothy | EVP, WW COB, MedTech | M - OptEx | $0.00 | +3,293 | 15.5K | +27% | $0 |
| DM | 2025-02-18 21:33 | 2025-02-14 | JNJ | Schmid Timothy | EVP, WW COB, MedTech | F - Tax | $156.37 | -832 | 14.5K | -5% | -$130.1K |
| D | 2025-02-18 21:33 | 2025-02-18 | JNJ | Schmid Timothy | EVP, WW COB, MedTech | S - Sale+OE | $156.15 | -403 | 15.1K | -3% | -$62.9K |
| DM | 2025-02-18 21:16 | 2025-02-13+ | JNJ | Wengel Kathryn E | EVP, Chief TO, Risk Off | M - OptEx | $0.00 | +8,625 | 96.7K | +10% | $0 |
| DM | 2025-02-18 21:16 | 2025-02-14+ | JNJ | Wengel Kathryn E | EVP, Chief TO, Risk Off | F - Tax | $156.58 | -3,296 | 94.3K | -3% | -$516.1K |
| DM | 2025-02-18 21:13 | 2025-02-13+ | JNJ | Wolk Joseph J | EVP, CFO | M - OptEx | $0.00 | +23.1K | 20.7K | New | $0 |
| DM | 2025-02-18 21:13 | 2025-02-14+ | JNJ | Wolk Joseph J | EVP, CFO | F - Tax | $156.58 | -9,080 | 14.0K | -39% | -$1.42M |
| D | 2025-02-18 21:11 | 2025-02-15 | JNJ | REED JOHN C | EVP, Innovative Medicine, R, D | M - OptEx | $0.00 | +1,350 | 15.9K | +9% | $0 |
| D | 2025-02-18 21:11 | 2025-02-18 | JNJ | REED JOHN C | EVP, Innovative Medicine, R, D | F - Tax | $156.15 | -385 | 15.5K | -2% | -$60.1K |
| DM | 2025-02-18 21:08 | 2025-02-13+ | JNJ | Taubert Jennifer L | EVP, WWC. Innovative Medicine | M - OptEx | $0.00 | +22.4K | 185.9K | +14% | $0 |
| DM | 2025-02-18 21:08 | 2025-02-14+ | JNJ | Taubert Jennifer L | EVP, WWC. Innovative Medicine | F - Tax | $156.62 | -10.3K | 178.0K | -5% | -$1.62M |
| DM | 2025-02-18 21:06 | 2025-02-13+ | JNJ | Swanson James D. | EVP, CIO | M - OptEx | $0.00 | +6,018 | 19.7K | +44% | $0 |
| DM | 2025-02-18 21:06 | 2025-02-14+ | JNJ | Swanson James D. | EVP, CIO | F - Tax | $156.54 | -1,740 | 18.8K | -8% | -$272.4K |
| DM | 2025-02-18 21:05 | 2025-02-13+ | JNJ | Mulholland Kristen | EVP, Chief HR Off | M - OptEx | $0.00 | +3,438 | 14.6K | +31% | $0 |
| DM | 2025-02-18 21:05 | 2025-02-14+ | JNJ | Mulholland Kristen | EVP, Chief HR Off | F - Tax | $156.44 | -1,008 | 14.1K | -7% | -$157.7K |
| DM | 2025-02-18 21:03 | 2025-02-13+ | JNJ | Forminard Elizabeth | GC, Executive VP | M - OptEx | $0.00 | +3,815 | 11.4K | +51% | $0 |
| DM | 2025-02-18 21:03 | 2025-02-14+ | JNJ | Forminard Elizabeth | GC, Executive VP | F - Tax | $156.32 | -1,253 | 10.9K | -10% | -$195.9K |
| DM | 2025-02-18 21:02 | 2025-02-13+ | JNJ | Duato Joaquin | CEO, COB, Dir | M - OptEx | $0.00 | +31.5K | 415.2K | +8% | $0 |
| DM | 2025-02-18 21:02 | 2025-02-14+ | JNJ | Duato Joaquin | CEO, COB, Dir | F - Tax | $156.48 | -13.7K | 406.8K | -3% | -$2.14M |
| DM | 2025-02-18 21:01 | 2025-02-13+ | JNJ | Decker Robert J | VP Corp. Ctrl | M - OptEx | $0.00 | +2,852 | 21.4K | +15% | $0 |
| DM | 2025-02-18 21:01 | 2025-02-14+ | JNJ | Decker Robert J | VP Corp. Ctrl | F - Tax | $156.46 | -824 | 21.0K | -4% | -$128.9K |
| DM | 2025-02-18 20:58 | 2025-02-13+ | JNJ | Broadhurst Vanessa | EVP, Gbl Corp Affairs | M - OptEx | $0.00 | +5,640 | 24.6K | +30% | $0 |
| DM | 2025-02-18 20:58 | 2025-02-14+ | JNJ | Broadhurst Vanessa | EVP, Gbl Corp Affairs | F - Tax | $156.55 | -1,880 | 23.6K | -7% | -$294.3K |
| D | 2025-02-11 19:43 | 2025-02-07 | JNJ | Duato Joaquin | CEO, COB, Dir | M - OptEx | $100.06 | +126.4K | 489.7K | +35% | +$12.64M |
| D | 2025-02-11 19:43 | 2025-02-07 | JNJ | Duato Joaquin | CEO, COB, Dir | F - Tax | $153.12 | -100.6K | 389.0K | -21% | -$15.41M |
| D | 2025-02-11 19:42 | 2025-02-07 | JNJ | Wengel Kathryn E | EVP, Chief TO, Risk Off | M - OptEx | $100.06 | +32.8K | 115.0K | +40% | +$3.28M |
Purchase Sale Sale after option exercise All abbreviations